The Latest Cardiac and Vascular News
AQUAPASS ECCON™ System delivered a >7x increase in net fluid loss in congested heart failure patients not responding to high-dose diuretics, with a consistently high responder rate (91%) and no device-related adverse events NEWTON, Mass., Nov. 5, 2026: AQUAPASS Medical, developer of a noninvasive, kidney-independent therapy, announced that the REFORM-HF […]
NEWTON, Mass. and SHEFAYIM, Israel, Aug. 10, 2026 /PRNewswire/ — AQUAPASS, developer of a noninvasive, kidney-independent therapy for fluid overload management in patients experiencing heart failure and chronic or end-stage kidney disease, announced completion of enrollment in its FDA…
